HIV and Tuberculosis: drug interactions between nevirapine (or efavirenz) and rifampicin / isoniazid in HIV-infected individuals and with active tuberculosis (Maputo, Mozambique, between 2007 and 2011)

This work is composed of two clinical studies in Maputo, Mozambique, from which participated in 570 patients with co-infection with HIV and tuberculosis. Its main objectives were: a) determine the pharmacokinetic parameters of rifampicin and isoniazid in the absence and presence of antiretroviral therapy (ART) and b) compare the plasma concentrations of nevirapine and efavirenz in effectiveness of treatment for tuberculosis and after their discontinuation . The two studies were of the clínicoANRS12146-CARINEMO trial whose aim was to compare the efficacy and tolerability of antiretroviral therapy based on nevirapine or efavirenz when co-administered with the standard antituberculous therapy. The treatment for tuberculosis was composed of daily doses of rifampicin and isoniazid for 6 months, pyrazinamide and ethambutol associated with the first two months. The ART was initiated between 4 and 6 weeks of treatment for tuberculosis and patients were randomized to receive nevirapine without scaled dose (200 mg twice daily) or efavirenz (600 mg once daily), both in combination with lamivudine and stavudine...